Please assess the completion status of the following clinical trial:

Trial Title: A Study of Mycobacterium w Plus Docetaxel for Hormone Refractory Metastatic Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed adenocarcinoma of the prostate with clinical or radiologic evidence of metastatic disease.~* Disease progression during antiandrogen therapy, having surgical or medical castration status.~* Karnofsky Performance Status 50-100~* Normal cardiac function~* Life expectancy at least 24 weeks.~* Laboratory criteria for eligibility will include~* A neutrophil count of at least 1500 per cubic millimeter~* A hemoglobin level of at least 9 gm%~* A platelet count of at least 1000,000 per cubic millimeter.~* A total bilirubin not grater than 1.5 times the upper limit of the normal range for each institution.~* Serum creatinine levels not more than 1.5 times the upper limit of the normal range~* Written informed consent~Exclusion Criteria:~* Prior treatment with cytotoxic agents or radioisotopes~* Estrogen use for at least three months~* History of another cancer within the preceding five years (except basal or squamous-cell skin cancer)~* Brain or leptomeningeal metastases~* Symptomatic peripheral neuropathy of grade 2 or higher~* Uncontrolled intercurrent illness that would limit compliance with study requirements

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 2 (Type: EXPERIMENTAL): Docetaxel+Mw
- 1 (Type: ACTIVE_COMPARATOR): Docetaxel

Based on this trial design, predict the completion outcome and termination type (if applicable).